Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Gilles Freyer^{1

2

3}, Anne Floquet^{4

5}, Olivier Tredan^{4

6}, Aurore Carrot^{4

7}, Carole Langlois-Jacques^{4

8}, Jonathan Lopez^{4

9}, Frédéric Selle^{4

10}, Cyril Abdeddaim^{4

11}, Alexandra Leary^{4

12}, Coraline Dubot-Poitelon^{4

13}, Michel Fabbro^{4

14}, Laurence Gladieff^{4

15}, Michele Lamuraglia^{4

16}

Affiliations

¹ Department of Medical Oncology, Lyon 1 University, Lyon, France. gilles.freyer@univ-lyon1.fr.
² GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, Paris, France. gilles.freyer@univ-lyon1.fr.
³ Institut de Cancérologie des HCL, Lyon, France. gilles.freyer@univ-lyon1.fr.
⁴ GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, Paris, France.
⁵ Department of Medical Oncology - Gynecological Tumors, Institut Bergonié, Bordeaux, France.
⁶ Medical Oncology, Centre Léon Bérard, Lyon, France.
⁷ EMR 3738, UFR Lyon-Sud, Université Lyon1, Lyon, France.
⁸ Biostatistics and Bioinformatics Department, Hospices Civils de Lyon, Lyon, France.
⁹ Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon, France.
¹⁰ Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
¹¹ Gynecologic Oncology Department, Centre Oscar Lambret, Lille, France.
¹² Oncology Department, Institut Gustave Roussy, Villejuif, France.
¹³ Medical Oncology, Institut Curie Saint Cloud, Paris, France.
¹⁴ Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.
¹⁵ Medical Oncology, Institut Claudius Regaud IUCT-Oncopole, Toulouse, France.
¹⁶ Medical Oncology, Institut de Cancérologie du CHUSE, Saint-Etienne, France.

Published Erratum

Gilles Freyer et al. Nat Commun. 2024.

. 2024 Jun 4;15(1):4753.

doi: 10.1038/s41467-024-48915-9.

¹ Department of Medical Oncology, Lyon 1 University, Lyon, France. gilles.freyer@univ-lyon1.fr.
² GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, Paris, France. gilles.freyer@univ-lyon1.fr.
³ Institut de Cancérologie des HCL, Lyon, France. gilles.freyer@univ-lyon1.fr.
⁴ GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, Paris, France.
⁵ Department of Medical Oncology - Gynecological Tumors, Institut Bergonié, Bordeaux, France.
⁶ Medical Oncology, Centre Léon Bérard, Lyon, France.
⁷ EMR 3738, UFR Lyon-Sud, Université Lyon1, Lyon, France.
⁸ Biostatistics and Bioinformatics Department, Hospices Civils de Lyon, Lyon, France.
⁹ Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon, France.
¹⁰ Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
¹¹ Gynecologic Oncology Department, Centre Oscar Lambret, Lille, France.
¹² Oncology Department, Institut Gustave Roussy, Villejuif, France.
¹³ Medical Oncology, Institut Curie Saint Cloud, Paris, France.
¹⁴ Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.
¹⁵ Medical Oncology, Institut Claudius Regaud IUCT-Oncopole, Toulouse, France.
¹⁶ Medical Oncology, Institut de Cancérologie du CHUSE, Saint-Etienne, France.

No abstract available

Erratum for

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Nat Commun. 2024. PMID: 38443333 Free PMC article. Clinical Trial.